Akdaş A, Dillioğlugil O, Cevik I, Ilker Y
Department of Urology, Marmara University School of Medicine, Istanbul, Turkey.
Eur Urol. 1994;25(4):299-303; discussion 304. doi: 10.1159/000475305.
In an attempt to enhance the success of prostate-specific antigen (PSA) in the diagnosis and staging of prostate carcinoma (PCa) the concept of PSA density (PSAD) has been introduced by Benson et al. Likewise a study to investigate the role of PSAD in 53 patients with PCa and 47 patients with benign prostatic hyperplasia (BPH) has been done. PSADs seemed to increase directly proportional to the grade in PCa and differed significantly between patient groups with BPH and localized+metastatic PCa, BPH and localized PCa, and localized PCa and metastatic PCa. Although 0.6 level for PSAD seemed to be a rational cut-off level in our study, this issue needs to be studied in multiple centers involving an increased number of patients for resolution.
为提高前列腺特异性抗原（PSA）在前列腺癌（PCa）诊断和分期中的成功率，Benson等人引入了PSA密度（PSAD）的概念。同样，一项针对53例PCa患者和47例良性前列腺增生（BPH）患者的研究，对PSAD的作用进行了调查。PSAD似乎与PCa的分级成正比增加，并且在BPH与局限性+转移性PCa患者组、BPH与局限性PCa患者组以及局限性PCa与转移性PCa患者组之间存在显著差异。尽管在我们的研究中，PSAD的0.6水平似乎是一个合理的临界值，但这个问题需要在多个中心开展涉及更多患者的研究来解决。
